ERBB2 and gastric cancer: Hou et al. showed that radiomic signatures can predict response to radiotherapy with an AUC of 0.749, while Yoon et al. reported AUCs of 0.75–0.77 in their small pilot study of 26 cases of HER2-positive gastric cancer treated with trastuzumab.32, 33